Cancer Drug Design and DiscoveryEdited by
- Stephen Neidle
- Stephen Neidle
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.
Translational researchers interested in cancer biology and medicine. Students in pharmacy, pharmacology, or medicinal and biological chemistry, as well as clinicians taking oncology options.
Published: November 2007
Imprint: Academic Press
- Section I. Basic Principles 1. Modern cancer drug discovery: Integrating targets, technologies and treatments2. Preclinical pharmacology and in vivo models 3. Clinical trial designs for more rapid proof-of-principle and approval
Section II. Methodology 4. Structural biology and anticancer drug design5. Natural product chemistry and cancer drug discovery 6. Pharmacokinetics & ADME optimization in drug discovery
Section III. Drugs in the clinic and laboratory7. Temozolomide: from cytotoxic to molecularly-targeted agent 8. Camptothecins for drug design, cancer cell death and gene targeting9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
Section IV. New Agents 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery11. Cell cycle inhibitors in cancer: current status and future directions 12. Inhibition of DNA repair as a therapeutic target 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways14. Heat shock protein-90-directed therapeutics and target validation15. Inhibitors of tumour angiogenesis16. The biology and oncology of RAF-ERK signalling P53 as a therapeutic target
Section V. The reality of cancer drugs in the clinic17. Cancer drug resistance 18. Failure Modes in Anticancer Drug Discovery and Development